Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426

Rini, Brian I. and Plimack, Elizabeth R. and Stus, Viktor and Waddell, Tom and Gafanov, Rustem and Pouliot, Frédéric and Nosov, Dmitry and Melichar, Bohuslav and Soulieres, Denis and Borchiellini, Delphine and Vynnychenko, Ihor O. and McDermott, Raymond S. and Azevedo, Sergio Jobim and Tamada, Satoshi and Kryzhanivska, Anna and Li, Chenxiang and Burgents, Joseph E. and Molife, L. Rhoda and Bedke, Jens and Powles, Thomas (2021) Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. Journal of Clinical Oncology, 39 (15 s.1). p. 4500. ISSN 0732-183X (Print); 1527-7755 (Electronic); 0732-183X (Linking)

Text Pembrolizumab-2021 Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) P. 4500.pdf Download (139kB)

Abstract

https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.4500

Item Type:	Article
Additional Information:	DOI: 10.1200/JCO.2021.39.15_suppl.4500 Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 4500-4500.
Subjects:	Urology Oncology
Divisions:	Departments > Department of Urology
Depositing User:	Елена Шрамко
Date Deposited:	13 Sep 2021 07:20
Last Modified:	13 Sep 2021 07:21
URI:	http://repo.dma.dp.ua/id/eprint/6902

Actions (login required)

View Item